Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBITDA Margin (2024 - 2025)

Silence Therapeutics' EBITDA Margin history spans 2 years, with the latest figure at 10917.65% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1098769.0% year-over-year to 10917.65%; the TTM value through Dec 2025 reached 14727.73%, down 1463239.0%, while the annual FY2025 figure was 12195.53%, 1208835.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 10917.65% at Silence Therapeutics, up from 20995.2% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 70.05% in Q4 2024 and bottomed at 20995.2% in Q3 2025.